Oragenics Inc OGEN

$0.20 -0.15 (-42.59%)

Valuation

Market cap
907,000
Revenue TTM
$0
Net income TTM
$-9,840,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
17,476,500
Avg volume
1,008,040
Day's range
$0.17 – $0.23
Shares out
4,512,000
Stochastic %K
15%
Beta
1.28
Analysts
—
Price target
$2.00

Price

Company profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper...

Show more

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
813 286 7900
Website
https://www.oragenics.com
Address
9015 Town Center Parkway, Suite 143, Lakewood Ranch, United States

Latest news

Stocktwits

RocketQueen Nov 15, 9:57 PM
$OGEN with nothing in the pipeline, expect an overnight R/S soon.
0 replies
RocketQueen Nov 15, 4:46 PM
$OGEN nothing in the pipe right now, and so expect a very deep correction that could dip below .10. I expect Janet is going to pivot to the next garbage bin scam with the upcoming reverse split. Reading between the lines, the nasal scam is over, and she'll likely pivot to the blood filtering units.
0 replies
RocketQueen Nov 15, 5:53 AM
$OGEN well, it's back to .20 already from the previous R/S and Janet has accomplished nothing. The clinical trial has been paused due to issues with the device. It's very unlikely the trials will continue due to their financial situation, and scam product.
0 replies
RocketQueen Nov 14, 1:17 AM
$OGEN Janet: .1667/30 = .005 Kim: .005/60 = .00008 For the upcoming months, take both numbers above and divide by a factor of ranging up to about 50 or so. Criminals.
0 replies
RocketQueen Nov 14, 12:09 AM
$OGEN little bit of a dead cat bounce with the high volume, but this is going to tank hard soon....Nothing in the pipe, and compounding issues with finances.
0 replies
topstockalerts Nov 13, 11:50 PM
$OGEN where do you think this goes from here?
1 replies
NMax Nov 13, 11:42 PM
$OGEN WARNING TO ORAGENICS MANAGEMENT: If this is repeated, you will almost definitely face prosecution: How did a $5,000 transaction potentially unlock MILLIONS of Oragenics shares? Follow the money. On July 2, 2025, Janet Huffman and the board of directors issued highly dilutive preferred shares amid extremely high $OGEN short interest. Here's the twist: ONE preferred share could convert into 25 common shares! With liquidity scarce, millions of new shares could suddenly become available, potentially providing an escape route for trapped shorts. What triggered this? A mere $5,000 share issuance to Dawson James for advisory fees. That transaction reportedly triggered an anti-dilution provision, slashing the Series H conversion price from $2.50 to $1.00. The result? 25 common shares for EVERY preferred share. Who benefited? Were recipients connected to short sellers? $5,000. Millions of potential shares. Who was this REALLY designed to benefit?
1 replies
Johnnytwofour Nov 13, 10:57 PM
$OGEN Looks like they are going to try and punch it through. 3rd times teh charm as they say.
0 replies